Pronostics and Medipan sign German assay deal
UK-based diagnostic firm Pronostics has signed a distribution deal with Germany's Medipan GmbH that will see the latter market the former's range of UltraPlex autoimmune disease biomarker assays in Germany and Austria. The Cambridge-headquartered firm explained that its German partner would use its established sales force to promote the ANA, Coeliac and Thyroid assay kits to hospitals and large private laboratories in the region.
Under the agreement, which provides Medipan with an exclusive UltraPlex license, the German firm could generate an estimated 2.0 million euros ($3.1 million) in revenue. Further financial details were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze